Overview
- Royal Philips announced it will buy Massachusetts-based SpectraWAVE, with financial terms not disclosed.
- SpectraWAVE’s portfolio includes HyperVue for high-definition coronary imaging and X1-FFR, which estimates fractional flow reserve from a single angiogram using AI.
- Philips plans to integrate these technologies with its Eagle Eye Platinum digital IVUS and OmniWire iFR devices for a more unified coronary workflow.
- CEO Roy Jakobs framed the deal as advancing AI-driven image-guided therapy, and SpectraWAVE’s Eman Namati said it could help standardize coronary care for more patients.
- Philips shares dipped in premarket trading after the news, and the company reiterated 2026 guidance that signals improving growth but below the 4.5% consensus and cautioned about intensifying tariff headwinds.